Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 2
2006 2
2007 3
2008 3
2009 1
2010 3
2011 7
2012 6
2013 7
2014 4
2015 10
2016 5
2017 7
2018 4
2019 10
2020 5
2021 10
2022 11
2023 10
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB; DEVOTE Study Group. Marso SP, et al. N Engl J Med. 2017 Aug 24;377(8):723-732. doi: 10.1056/NEJMoa1615692. Epub 2017 Jun 12. N Engl J Med. 2017. PMID: 28605603 Free PMC article. Clinical Trial.
Prolyl isomerase Pin1 in metabolic reprogramming of cancer cells.
Nakatsu Y, Yamamotoya T, Ueda K, Ono H, Inoue MK, Matsunaga Y, Kushiyama A, Sakoda H, Fujishiro M, Matsubara A, Asano T. Nakatsu Y, et al. Among authors: kushiyama a. Cancer Lett. 2020 Feb 1;470:106-114. doi: 10.1016/j.canlet.2019.10.043. Epub 2019 Oct 31. Cancer Lett. 2020. PMID: 31678165 Review.
Development of Pin1 Inhibitors and their Potential as Therapeutic Agents.
Nakatsu Y, Matsunaga Y, Ueda K, Yamamotoya T, Inoue Y, Inoue MK, Mizuno Y, Kushiyama A, Ono H, Fujishiro M, Ito H, Okabe T, Asano T. Nakatsu Y, et al. Among authors: kushiyama a. Curr Med Chem. 2020;27(20):3314-3329. doi: 10.2174/0929867325666181105120911. Curr Med Chem. 2020. PMID: 30394205 Review.
Gut Microbiota as a Therapeutic Target for Metabolic Disorders.
Okubo H, Nakatsu Y, Kushiyama A, Yamamotoya T, Matsunaga Y, Inoue MK, Fujishiro M, Sakoda H, Ohno H, Yoneda M, Ono H, Asano T. Okubo H, et al. Among authors: kushiyama a. Curr Med Chem. 2018;25(9):984-1001. doi: 10.2174/0929867324666171009121702. Curr Med Chem. 2018. PMID: 28990516 Review.
100 results